Comparison of 2',3'-Dideoxyinosine (Didanosine, ddI) and Zidovudine in Therapy of Patients With the AIDS Dementia Complex
Status:
Completed
Trial end date:
1992-09-01
Target enrollment:
Participant gender:
Summary
To compare the safety and effectiveness of orally administered didanosine (ddI) with high
dose orally administered zidovudine (AZT) in patients who develop or exhibit progression of
the AIDS dementia complex (ADC) and who have not previously been intolerant to AZT at doses
of up to 1000 mg/day.
HIV-infected or AIDS patients may develop ADC which causes damage to the nervous system. ADC
may be caused by some action of the AIDS virus on the nervous system, although similar
problems can be caused by other infections because the AIDS virus lowers the body's ability
to fight other infections. It is important to determine whether symptoms are due to ADC or to
some other infection since treatment varies for different conditions. AZT has been shown to
be beneficial to people with ADC although its effectiveness has only been studied in a small
number of patients. Studies suggest that higher doses of AZT are more likely to be effective
than standard doses in improving symptoms of ADC.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)